| INTRODUCTION
Nonselective beta-adrenergic blockers (NSBB) constitute the backbone of the management of portal hypertension in patients with cirrhosis, both in the prevention of first variceal haemorrhage and its recurrence.
1 NSBB reduce portal pressure by decreasing portal venous inflow through a decrease in cardiac output (b-1 adrenergic blockade) and, more importantly, through splanchnic vasoconstriction (b-2 adrenergic blockade that allows an unopposed vasoconstrictive alpha-adrenergic effect on the splanchnic vasculature). Because NSBB act on one of the main pathophysiological mechanisms that maintain portal hypertension, their use has been associated not only to a decreased incidence of variceal haemorrhage but also to a reduction in the development of other complications of cirrhosis (ascites and encephalopathy) and an improved survival. 2, 3 However, a single-centre observational study by Serst e et al suggested that, in patients with cirrhosis and refractory ascites, those on propranolol had a higher mortality, even after adjustment for severity of liver disease. 4 A subsequent retrospective study showed an increased mortality in patients with spontaneous bacterial peritonitis but not in those with refractory ascites. 5 Subsequent studies performed in large cohorts of outpatients with cirrhosis and ascites found either no difference 6 or even an improved survival in patients treated with NSBB, 7, 8 including those with refractory ascites. A third study based on a European consortium of hospitalised patients with acute-on-chronic liver failure
showed an improved survival for those admitted on beta-blockers, and suggested an anti-inflammatory effect. 9 The determinants of BB reinitiation after discontinuation are, however, unclear.
The aim of our study was to compare, in a North American cohort of hospitalised patients with decompensated cirrhosis and ascites (refractory or not), the effect of beta-blockers (BB) on survival. The study also aimed at investigating predictors of betablocker discontinuation during hospitalisation and its effect, if any, on mortality, as well as factors that led to BB reinitiation.
| ME TH ODS
This is a multicentre, observational study of hospitalised patients with cirrhosis enrolled between January 2014 and September 2015 in the NACSELD (North American consortium for the study of endstage liver disease) cohort. 10, 11 NACSELD is a consortium of 16 tertiary-care hepatology centres that prospectively enrols non-electively admitted patients with cirrhosis and follows them through hospitalisation and 12-month post-discharge. The study protocol has been approved by the Institutional Review Boards in all participating centres and all patients or their family members provided written informed consent for inclusion into the study. on or off BB at the time of admission
As shown in Table 1 , patients in the BB group were more likely to have medium/large varices, a history of variceal haemorrhage, diabetes and to be on statins. Patients on BB had a lower heart rate without any differences in mean arterial pressure (86 AE 14 mmHg in both groups) or MELD score (20 in both groups) and a lower platelet count.
T A B L E 1 Characteristics at admission of all patients with ascites
All patients with ascites (n = 718)
Not on beta-blockers (n = 411)
On beta-blockers (n = 307) 
.003
Heart rate (bpm) 86 AE 17 (n = 716) 90 AE 16 (n = 409) 80 AE 17 (n = 307) <.001
Platelet count 112 AE 73 (n = 708) 119 AE 76 (n = 402) 104 AE 66 (n = 306) .004
Creatinine (mg/dL) 1.6 AE 1.4 (n = 715) 1.6 AE 1.4 (n = 408) 1.6 AE 1.3 (n = 307) .62
Serum Na (mEq/L) 133 AE 6 (n = 713) 133 AE 6 (n = 406) 134 AE 6 (n = 307) .030
Child score 10 AE 2 (n = 631) 10 AE 2 (n = 358) 10 AE 2 (n = 273) .67
Oesophageal varices
No or small Medium/large
n in parentheses represents the number of patients for which data for that particular variable were available. BMI, body mass index; HCV, hepatitis C virus infection; INR, international normalised ratio; MAP, mean arterial pressure; MELD, model for end-stage liver disease; Na, sodium; NASH, non-alcoholic steatohepatitis; WBC, white cell count. It is interesting to note that patients on NSBB had exactly the same MAP as those not on NSBB.
Notably, patients on BB had a lower admission WBC (7.4 AE 4.4 vs 8.7 AE 5.8 in the BB vs the non-BB group, respectively, P<.001).
In-hospital mortality was not different between groups, with a death rate of 13% (39/307) in the BB group and of 14% (56/411) in the non-BB group (P = .719) in a mean follow-up time of 15 AE 28 days (0 to 375). The probability of survival was not different between study groups (log rank P = .5289; Wilcoxon P = .6392) (Figure 1 ). On univariate Cox analysis, patients who died had a significantly lower MAP and serum sodium, higher temperature, MELD (and its components) and Child-Turcotte-Pugh (CTP) scores on admission than those who did not die (Table S1 ). On Cox regression analysis that included MAP, temperature, Na and MELD (or CTP score in another model) plus BB on admission (vs not on BB at admission), the only variables that were significant were temperature and the MELD score (HR did not show any differences in mortality (univariate analysis, log rank) nor was it significant on Cox analysis (data not shown). Only 25 patients were transplanted, of which 11 were on BB.
| Comparison between "patients with refractory
ascites" on or off BB at the time of admission
As shown in Table 2 , of 366 patients with refractory ascites, 167 (46%) were on BB on admission, while 199 (54%) were not. Similar to results from the overall group, patients taking a BB group were more likely to have large varices and to be on statins, they had a lower heart rate without a significant difference in mean arterial pressure (85 AE 14 in both groups, P = .91) and a lower platelet count. Notably, admission WBC was lower in patients on BB (7.6 AE 4.6 v 8.9 AE 5.5, P = .0104). Unlike the overall group, patients in the BB group were more likely to be male (71% vs 59%) and to have a lower MELD score (19 AE 2 vs 21 AE 7, P = .024).
Mortality was not different between study groups. In a mean follow-up period of 14 AE 24 days (range 0 to 286 days), 54/366 (15%) died, 19/167 (12%) in the BB group and 35/199 (17%) in the non-BB group (P = .4315). The probability of survival was not statistically significantly different between study groups (log rank P = .1085;
Wilcoxon P = .2946) (Figure 2 ).
On univariate Cox analysis (Table S3) did not show any differences between them neither in mortality nor in their lack of effect in predicting death (data not shown).
| Comparison of patients on BB at admission who did vs did not discontinue BB during hospitalisation
Of the 307 patients on BB at admission, BBs were discontinued in 151 patients (49%) during hospitalisation. The mean time between admission and BB discontinuation was 18 AE 24 days (range 1-169 days). In patients with refractory ascites, BB were discontinued in 44% (74/167) compared to 55% (77/140) BB discontinuation in patients with nonrefractory ascites (P = .07).
As shown in Table 3 , patients who discontinued BB had, on admission, a lower MAP and a higher MELD and were more likely to have been admitted with an infection, have developed an infection during admission, or developed AKI, compared to patients who did not discontinue BB. Despite being significantly sicker, those who discontinued BB had a similar probability of survival compared to those who did not discontinue BB (log rank P = .4552; Wilcoxon P = .7106) (Figure 3 ) even when only those with refractory ascites were considered (log rank P = .9741; Wilcoxon P = .3160).
Compared to admission values, patients who discontinued BB had significantly lower MAP and Child score at time of BB discontinuation (the latter perhaps as a result of albumin infusions and increased serum albumin). Serum albumin increased and serum creatinine and MELD score were unchanged (Table S5) | 81 serum creatinine (HR 1.284 (95% CI 1.040-1.586), but not serum sodium, were independent predictors of BB discontinuation. When looking at the specific criteria recommended by the Baveno consensus, 12 ie systolic blood pressure <90 mmHg, serum sodium <130 mEq/L or the presence of acute kidney injury, patients meeting any of these criteria were significantly more likely to discontinue BB (65% of patients with ascites, 69% of patients with refractory ascites) than those not meeting such criteria (P<.0001).
| Analysis of patients who discontinued BB and then reinitiated them during hospitalisation
Of 151 patients in whom BB were discontinued, they were reinitiated in 61 (40%) during hospitalisation. When comparing characteristics at discontinuation to those at reinitiation, the main factor that determined reinitiation was blood pressure (systolic, diastolic and mean arterial pressure) (Table S6 ).
| DISCUSSION
Nonselective beta-adrenergic blockers (NSBB) have been shown to prevent first and recurrent variceal haemorrhage in patients with cirrhosis and, in haemodynamic responders, BB have also been shown to prevent decompensation and death. 3 The effect appears to be independent of the presence or absence of ascites as demonstrated in 2 meta-analyses: one including 11 RCTs of BB for primary prophylaxis of variceal haemorrhage (VH) that demonstrated NSBB lowered first bleeding rates in patients with and without ascites 13 ; and the other was a meta-analysis of 12 RCTs on secondary prophylaxis of VH that showed a significant reduction in both rebleeding and death in NSBB-treated patients with "severe" liver disease. 14 The main pathophysiologic mechanism in patients with cirrhosis and ascites is splanchnic and systemic vasodilatation that leads to activation of neuro-humoral systems, sodium and fluid retention, resulting in increased cardiac output, and a hyperdynamic circulatory Albumin (g/dL) 2.9 AE 0.6 (n = 342) 2.9 AE 0.7 (n = 185) 2.8 AE 0.6 (n = 157) .005
Bilirubin ( .003 n in parentheses represents the number of patients for which data for that particular variable were available.
state. 15 In patients with refractory ascites, these abnormalities are maximal and a relative decrease in cardiac output can lead to a decrease in renal perfusion and to hepatorenal syndrome. 16 Betablockers could, at least theoretically, precipitate this decrease in cardiac output and lead to renal dysfunction and death. Therefore, it is plausible that BB use could lead to a higher mortality in patients with refractory ascites as suggested by an observational study performed in 151 patients. 4 Another retrospective study in 182 patients on BB failed to show a greater mortality in patients with refractory ascites but showed a higher mortality in patients with spontaneous bacterial peritonitis. 5 Subsequent retrospective studies including larger number of patients with ascites and/or refractory ascites (a collective of over 2000 patients) have shown that BB use is either unrelated to an increased mortality, 6 or is actually associated with an improved survival. 7, 8 In fact, a recent meta-analysis including these observational studies and randomised studies of BB in the prevention of VH, Not on BB,number at risk
F I G U R E 2 Probability of survival in patients with refractory ascites on BB at admission (discontinuous line) vs those not on BB at admission (continuous line)
T A B L E 3 Characteristics at admission of patients with ascites who discontinued vs those who did not discontinue BB during hospitalisation
Did not discontinue beta-blockers (n = 156) .65
n in parentheses represents the number of patients for which data for that particular variable were available.
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shows that BB use was not associated with increased all-cause mortality in patients with ascites, nonrefractory ascites alone or refractory ascites alone.
17
A survival benefit of BB was demonstrated in a study performed as part of a European consortium (CANONIC) in hospitalised patients with acute-on-chronic liver failure, 9 the stage of cirrhosis associated with the highest short-term mortality and in which the main pathogenic mechanism is systemic inflammation leading to worsening vasodilatation and multi-organ failure. 18 Because patients on NSBB had a lower WBC count on admission compared to those not on BB, an anti-inflammatory effect of NSBB was suggested in that study. 19 Our study was performed in patients with cirrhosis and ascites recruited in 7 of the 16 centres that compose a North American consortium (NACSELD) that prospectively collects data of non-electively admitted patients to centres in the United States and Canada.
We show that BB use in hospitalised cirrhotic patients with ascites is not associated with an increased mortality compared to non-BB users, even in those with refractory ascites. The probability of survival was the same in BB users vs non-users both in patients with ascites overall and in patients with refractory ascites. Importantly, as demonstrated by the European consortium, we found that patients on BB had a lower WBC count on admission.
One novel aspect of our study is the analysis of discontinuation and reinitiation of BB in this patient population. BB were discontinued during hospitalisation in about half the patients. This was primarily driven by a decrease in blood pressure (systolic, diastolic and mean arterial pressure) mostly in the setting of an infection and an acute kidney injury. Notably, even though patients who discontinued BB were sicker (higher MELD and lower MAP), their probability of survival was not different compared to those in whom BB were not discontinued, demonstrating that the strategy of discontinuing BB under these circumstances does not have a deleterious effect on outcome. In fact, when evaluating published studies on BB use in cirrhosis, those that show a deleterious effect of BB on survival are those that show a significantly lower MAP in the BB group. 20 In the most recent propensity score-matched study, there was a relationship between the dose of propranolol and survival, with doses lower than 160 mg/day associated with a lower mortality. 8 Although the dose-effect relationship with MAP was not examined in our study, it could be assumed that larger doses would be associated with larger decreases in MAP and worse outcomes.
In the recent Baveno portal hypertension workshop, consensus among experts concluded that the dose of BB should be reduced or BB discontinued in the setting of a systolic blood pressure <90 mmHg, hyponatremia (serum sodium <130 mEq/L) or the development of acute kidney injury. Our data largely validate these consensus recommendations, with around two-thirds of patients with ascites who met any of these criteria having BB discontinued; however, this discontinuation was driven mostly by a decrease in blood pressure.
Notably, BB could be reinitiated in 40% of patients prior to discharge and, not surprisingly, the main driver of BB reinitiation was once again an increase in blood pressure. This relatively large proportion of inpatients who had their BB reinstated despite going through infections, AKI and hypotensive episodes, suggests that clinical practice in North
America is cognizant of the potential benefits of BB therapy despite the mixed literature surrounding their discontinuation.
Even though data collection at admission was prospective, data on discontinuation and reinitiation of BB during hospitalisation were retrospective and therefore there is potential for selection bias.
There is no common protocol among centres for discontinuation of BB but, because all centres are academic centres, they are more likely to follow guidelines regarding discontinuation of BB and this is in fact reflected in our results. However, our conclusions may not apply to those admitted to nonspecialist centres.
In conclusion, this large cohort of North American patients with cirrhosis and ascites in whom data were collected prospectively at admission, demonstrates that BB use is safe in hospitalised patients with ascites and, specifically, in those with refractory ascites. We also show that BB discontinuation is mostly driven by a low mean arterial pressure in these patients and that, in this setting, BB discontinuation has no effect on survival and would constitute a best practice. Importantly, we demonstrate that BB can be reinitiated in 40%
of the patients prior to discharge and this practice is driven by an increase in blood pressure. Our study also supports a potential antiinflammatory effect of BB observed in a cohort of patients with acute-on-chronic liver failure 9 and indicates that, in general, unless there is a decrease in mean arterial pressure, BB should not be discontinued in patients with ascites/refractory ascites.
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